Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 14, 107 (2008)
doi:10.1038/nm0208-107
Europe pledges billions to solve its drug development woes
Virginia Hughes1
- New York
When the Danish biopharmaceutical company Action Pharma incorporated in May 2000, it had four academic founders and AP214—an anti-inflammatory drug candidate designed to prevent organ failure after heart surgery. However, despite the promise of AP214 and the scientific credentials of its creators, Action Pharma had a tough time attracting investors.
To read this story in full you will need to login or make a payment (see right).
